The application of Lucilia sericata larvae to chronic, infected wounds results in the rapid elimination of infecting microorganisms, including MRSA. Previously, we demonstrated in vitro antibacterial activity of native excretions/secretions (nES) from L. sericata and partially purified two low mass antibacterial compounds with masses of 0.5-10 kDa and <500 Da. The present study reports the antibacterial effects of the <500 Da fraction (ES<500) on the growth and morphology of a range of bacteria, including 12 MRSA strains. Distinct morphological changes were observed in Bacillus cereus and Escherichia coli following exposure to ES<500. Flow cytometry and confocal microscopy analyses, in conjunction with turbidometric and CFU assays, revealed bacteriostatic activity of nES against S. aureus and E. coli. ES<500 also demonstrated bacteriostatic activity against S. aureus, however, bactericidal activity and the induction of a viable but non-culturable state were observed with ES<500-treated E. coli. © 2008 Elsevier Masson SAS. All rights reserved.
CITATION STYLE
Bexfield, A., Bond, A. E., Roberts, E. C., Dudley, E., Nigam, Y., Thomas, S., … Ratcliffe, N. A. (2008). The antibacterial activity against MRSA strains and other bacteria of a <500 Da fraction from maggot excretions/secretions of Lucilia sericata (Diptera: Calliphoridae). Microbes and Infection, 10(4), 325–333. https://doi.org/10.1016/j.micinf.2007.12.011
Mendeley helps you to discover research relevant for your work.